Oncobiologics (OTLK) Stock Price, News & Analysis

Company Overview

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets.

The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.

Key Stats

• Today's Range: $0.63 to $0.65
• 50-Day Range: $0.61 to $1.73
• 52-Week Range: $0.16 to $2.54
• Volume: 2.30 million shs
• Average Volume: 13.04 million shs
• Market Capitalization: $157.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.20
• Consensus Rating: Hold

Oncobiologics Stock Analysis - MarketRank™

Oncobiologics scored higher than 68% of companies evaluated by MarketBeat, and ranked 259th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Oncobiologics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Oncobiologics has a consensus price target of $5.20, representing about 717.6% upside from its current price of $0.64.

Amount of Analyst Coverage

Oncobiologics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncobiologics are expected to grow in the coming year, from ($0.47) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncobiologics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncobiologics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.77% of the float of Oncobiologics has been sold short.

Short Interest Ratio / Days to Cover

Oncobiologics has a short interest ratio ("days to cover") of 1.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncobiologics has recently increased by 65.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncobiologics does not currently pay a dividend.

Dividend Growth

Oncobiologics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.36

News Sentiment

Oncobiologics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Oncobiologics this week, compared to 3 articles on an average week.

Search Interest

Only 14 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

MarketBeat Follows

9 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Oncobiologics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $2,600,167.00 in company stock, which represents 1.6793% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Oncobiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,600,167.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Oncobiologics is held by insiders.

Percentage Held by Institutions

11.20% of the stock of Oncobiologics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/15/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OTLK
• CIK: 1649989
• Web: www.outlooktherapeutics.com
• Phone: (609) 619-3990
• Fax: N/A
• Employees: 20
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Oncobiologics: $5.20
• High Price Target: $10.00
• Low Price Target: $1.60
• Potential Upside/Downside: +712.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.42 million
• Net Margins: N/A
• Pretax Margin: -18,772.37%
• Return on Equity: N/A
• Return on Assets: -254.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: -$1.16 million
• Price / Sales: -133.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.60) per share
• Price / Book: -1.07

Miscellaneous

• Outstanding Shares: 243,448,000
• Free Float: 239,066,000
• Market Cap: $155.81 million
• Optionable: Optionable
• Beta: 0.74